Strasbourg, France, May 22, 2026, 5:45 p.m. CET - The Combined Ordinary and Extraordinary General Meeting of Transgene's shareholders was held today (May 22, 2026) at 11:00 a.m. CET at the Company's headquarters (400 boulevard Gonthier d'Andernach - Parc d'Innovation - 67400 Illkirch-Graffenstaden, France).
The Combined General Meeting was chaired by Alessandro Riva, Chairman and Chief Executive Officer. In addition to approving the statutory and consolidated financial statements for the fiscal year ended December 31, 2025, and the "Say on Pay" resolutions, the Combined General Meeting was also called to vote on all resolutions submitted to it, notably regarding the renewal of Directors' terms of office, financial authorizations, and delegations of authority granted to the Board of Directors to operate on the Company's share capital.
All resolutions recommended for approval by the Board of Directors were adopted by the shareholders.
In this respect, the Combined General Meeting notably renewed the terms of office of the following Board Members' mandates:
- TSGH, represented by Sandrine Flory, and Mr Benoît Habert as non-independent Directors;
- Ms Emmanuelle Quilès, and Ms Carol Stuckley as independent Directors.
The Combined General Meeting also approved the nomination of two new independent Directors:
- Ms Dorothea Ledergerber, and
- Ms Solange Peters.
Following the General Meeting, Transgene's Board of Directors is composed of the following members:
- Alessandro Riva;
- Michel Baguenault de Puchesse;
- Jean-Luc Bélingard;
- Jean-Yves Blay (Independent);
- Sandrine Flory (representing TSGH);
- Benoît Habert;
- Dorothea Ledergerber (Independent);
- Solange Peters (Independent);
- Emmanuelle Quilès (Independent);
- Carol Stuckley (Independent).
The Board of Directors is composed of 10 members. In terms of independence and gender diversity, it complies with the applicable regulations, with 5 independent directors out of 10 (i.e., 50%) and 5 women out of 10 (i.e., also 50%).
Detailed voting results are available on Transgene's website, under the heading Investors > General Meeting.
The replay of the Combined General Meeting is available via Transgene's website and here (in French).
Dorothea Ledergerber, PharmD, PhD, independent Director (59, German nationality) currently serves as Multi-Site Head of Drug Product Operations at the Siegfried Group and also sits on the board of directors of the CDMO DINAMIQS. A pharmacist, by training with a PhD in pharmaceutical sciences, she has over 25 years of experience in the pharmaceutical and biotechnology industries. She has held leadership roles at Novartis, where she notably led industrial operations in Europe and helped establish the group's first commercial production unit for cell and gene therapies. She also served as Chief Technical Officer at Tigen Pharma, a company specializing in autologous cell therapies. Ms. Ledergerber possesses recognized expertise spanning the entire pharmaceutical value chain, from development to production.
Dorothea Ledergerber is a German citizen.
Prof Solange Peters, MD, PhD, independent Director is a full professor and director of the Oncology Department, as well as chair of Medical Oncology at the University Hospital of Lausanne in Lausanne, Switzerland. She received both her doctorate in medicine and PhD from the University Hospital of Lausanne. After completing her clinical education in medical oncology and molecular biology in Switzerland and Italy, Prof. Peters has specialized in thoracic tumors, lung cancer, and pleural tumors. Her main fields of interest are new biomarkers discovery and validation in preclinical and clinical settings, multimodality strategies for locally advanced non-small cell lung cancer (NSCLC), as well as cancer immunotherapy. Parallel, she acts as the scientific committee chair and Foundation Council member of the European Thoracic Oncology Platform (ETOP). She also acts as the Strategic Advisory Board President of Paris Saclay Cancer Cluster, as well as President of Oncosuisse, the Swiss Cancer umbrella organization. She also has the role of President of the Swiss Academy of Multidisciplinary Oncology (SAMO) and is Vice Director of the Swiss National Cancer League. Prof. Peters is active in the educational programs of the International Association for the Study of Lung Cancer (IASLC) and European Society for Medical Oncology (ESMO) - where she created the Women for Oncology Committee and for which she was the youngest President ever for an extended time of 3 years 2020-2022. She is part of the Board of Directors of Galenica SA. Professor Peters has authored more than 500 peer-reviewed manuscripts and book chapters, acts as Associate Editor of the Annals of Oncology, and of ESMO Open, past Editor in Chief of Lung Cancer, past Deputy Editor of the Journal of Thoracic Oncology (JTO) for several years, and serves on the editorial board of several other oncology journals.
Solange Peters is a Swiss citizen.
***
Contacts
| Transgene: | |
| Media: | Investors & Analysts: |
| Caroline Tosch | Lucie Larguier |
| Corporate and Scientific Communications Manager | Chief Financial Officer (CFO) |
| +33 (0)3 68 33 27 38 | Nadege Bartoli |
| communication@transgene.fr | Investor Relations Analyst and Financial Communications Officer |
| MEDiSTRAVA | +33 (0)3 88 27 91 00/03 |
| Frazer Hall/Sylvie Berrebi | investorrelations@transgene.fr |
| + 44 (0) 203 928 6900 | |
| transgene@medistrava.com |
About Transgene
Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. The Company's clinical-stage programs consist of a portfolio of viral vector-based immunotherapeutics. TG4050, the first individualized therapeutic vaccine based on the myvac® platform is the Company's lead asset, with demonstrated proof of principle in patients in the adjuvant treatment of head and neck cancers. The Company has other viral vector-based assets, including BT-001, an oncolytic virus based on the Invir. IO® viral backbone, which is in clinical development. The Company also conducts innovative discovery and preclinical work, aimed at developing novel viral vector-based modalities.
With Transgene's myvac® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations, identified and selected through advanced Artificial Intelligence technologies.
With its proprietary platform Invir. IO®, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses.
Additional information about Transgene is available at: www.transgene.com
Follow us on social media: LinkedIn: @Transgene?-?X: @TransgeneSA - Bluesky: @Transgene
Disclaimer
This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company's activities, perspectives, financial situation, results, regulatory authorities' agreement with development phases, and development. The Company's ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Universal Registration Document, available on the AMF website (http://www.amf-france.org) or on Transgene's website (www.transgene.com). Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.
